Arrowhead Pharmaceuticals ARWR
NASDAQ ARWR
$58.84 -0.08 (-0.14%)
At close: Oct 21, 2026 · 4:00 PM EDT

Arrowhead Pharmaceuticals (ARWR) Short-Term Debt repayments (2025)

Updated

Arrowhead Pharmaceuticals' Short-Term Debt repayments came in at $50 million for fiscal Q3 2025 (quarter ended Jun 30, 2025).

Analysis

Arrowhead Pharmaceuticals (ARWR) Short-Term Debt repayments (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ST Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 6.45 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Arrowhead Pharmaceuticals 8.47 Bn 3.24 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 50.00 Mn
API Access

Arrowhead Pharmaceuticals Short-Term Debt repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt-repayments&ticker=ARWR&period=max&api_key=YOUR_API_KEY